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Abstract
Regulatory T (TREG) cells play an important role in maintaining immune tolerance and avoiding autoimmunity. We analyzed the
expression of membrane molecules in TREG and effector T cells in systemic lupus erythematosus (SLE). TREG and effector T cells
were analyzed for the expression of CTLA-4, PD1, CD28, CD95, GITR, HLA-DR, OX40, CD40L, and CD45RO in 26 patients with
active disease, 31 with inactive disease, and 26 healthy controls. TREG cells were defined as CD25+/highCD127Ø/lowFoxP3+, and
effector T cells were defined as CD25+CD127+FoxP3Ø. The ratio of TREG to effector T cells expressing GITR, PD1, HLA-DR,
OX40, CD40L, and CD45RO was determined in the three groups. The frequency of TREG cells was similar in patients with SLE and
controls. However, SLE patients had a decreased frequency of CTLA-4+TREG and CD28+TREG cells and an increased frequency
of CD40L+TREG cells. There was a decrease in the TREG/effector-T ratio for GITR+, HLA-DR+, OX40+, and CD45RO+ cells, and
an increased ratio of TREG/effector-T CD40L+ cells in patients with SLE. In addition, CD40L+TREG cell frequency correlated with
the SLE disease activity index (P=0.0163). In conclusion, our findings showed several abnormalities in the expression of functionally
critical surface molecules in TREG and effector T cells in SLE that may be relevant to the pathogenesis of this disease.
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Introduction
Understanding the pathophysiology of autoimmune
diseases, and systemic lupus erythematosus (SLE) in
particular, remains a great elusive challenge, but important
advances have been achieved. With respect to cellular
immunology, the characterization of regulatory T (TREG)
cells has had a considerable impact on the understanding
of some aspects of several autoimmune diseases. TREG
cells play an important role in maintaining immune
tolerance (1). Their characteristic marker is the transcrip-
tion factor FoxP3 (2), and an important advance in the
study of TREG cells was the demonstration that low CD127
and high CD25 expression levels have a strong correlation
with FoxP3 expression, therefore providing a valuable way
to identify TREG cells based on membrane markers (3,4).
Profound deficiency in FoxP3+ TREG cells can potentially
lead to the activation and expansion of rare self-reactive T
cells, thus inducing a wide spectrum of autoimmune/
inflammatorymanifestations. In humans, this is exemplified
by mutations in the FOXP3 gene that can result in the rare
X-linked immunodeficiency syndrome known as IPEX
(immune deregulation, polyendocrinopathy, enteropathy
X-linked syndrome), a severe and rapidly fatal disorder with
frequent autoimmune traits, such as thrombocytopenia and
hemolytic anemia (5). It is not surprising that a number of
TREG cell defects have been reported in patients with
autoimmune diseases (6).
Studies in SLE patients have reported conflicting data
regarding the frequency, phenotype, and function of these
cells. The heterogeneity in findings of decreased (7-13),
normal, or even increased frequency of TREG cells in
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SLE (14-18) may be partially due to the criteria adopted in
each study to define the TREG cell phenotype. We
recently demonstrated that the CD25high gate, considered
by some studies as characteristic for TREG cells,
contains high levels of activated effector T cells in the
active stages of SLE (4). Additional factors contributing to
the heterogeneity of results include the clinical definition
of disease activity, influence of immunosuppressant
therapy, and technical aspects of in vitro cell handling,
as well as flow cytometry analysis.
Several surface molecules are crucial for TREG cell
survival and function. Some of these are constitutively
expressed in TREG cells but are only expressed after
activation in other T cell subsets. One such molecule is
cytotoxic T lymphocyte antigen 4 (CTLA-4), whose con-
stitutive expression in TREG cells was shown to be under
the control of FoxP3 (19). CTLA-4 plays an important role
in contact-dependent suppression by means of the inter-
action between CTLA-4 on TREG cells with CD80/CD86
on effector T cells, leading to downregulation of the latter.
Alternatively, CTLA-4 on TREG cells can interact with
CD80/CD86 on antigen-presenting cells and induce
indoleamine dioxygenase expression in these cells. This
enzyme depletes tryptophan and leads to the formation of
toxic metabolites, resulting in local suppression of T cell
proliferation (20). The closely related molecule PD-1 also
acts to suppress T cell immune responses (20).
In addition, the expression of OX40, CD40L, and GITR
(glucocorticoid-induced tumor necrosis factor receptor) at
the effector T cell surface could dictate the resistance
of effector T cells to TREG suppression. OX40 controls
the development of effector and memory T cells and is
protective in the settings of cancer and infectious
diseases but may be pathogenic in the setting of
autoimmunity and allergy. As described by So et al.
(21), OX40 displays dual activities supporting effector T
cell development and concomitantly preventing the gen-
eration and activity of TREG cells. GITR is constitutively
expressed by TREG cells but is also expressed by
activated effector T cells. Previous studies have shown
that the binding of GITR leads to antigen-nonspecific
proliferation and activation of TREG cells, whereas the
engagement of GITR renders effector T cells resistant to
TREG suppression (22). These elements suggest that the
balance of several surface molecules in TREG and
effector T cells may be relevant to the final fate of the
interaction between these two T cell subsets. In the
present study, we investigated the balance of TREG and
effector T cells bearing the surface molecules CTLA-4,
PD-1, OX40, GITR, CD40L, CD28, CD95, CD45RO, and
HLA-DR in patients with active and inactive SLE.
Material and Methods
Study population
Patients were recruited from the Clinic at Universidade
Federal de Sa˜o Paulo, Sa˜o Paulo, SP, Brazil. All patients
met the revised criteria of the American College of
Rheumatology for SLE (23). Disease activity was rated
by the SLE disease activity index (SLEDAI) (24) Active
disease was defined as SLEDAI >6, and inactive disease
was SLEDAI=0. There were 26 patients with active
disease (SLEDAI=10.17±3.7) and 31 patients with no
sign of disease activity (SLEDAI=0). Twenty-six healthy
volunteers (24 females and 2 males) were recruited from
the hospital staff. All 26 patients with active SLE (A-SLE)
were female; the 31 patients with inactive SLE (I-SLE)
included 30 females and 1 male. There were no significant
differences in the mean ages of healthy controls
(29.81±8.2 years), A-SLE patients (36±11 years), and
I-SLE patients (37±13 years). The mean disease
duration was 3.7±2.5 years for patients with SLE. Most
A-SLE patients were treated with monthly intravenous
cyclophosphamide pulse therapy, and blood was drawn
immediately before administration of this immunosup-
pressant. In addition, 15.4% of A-SLE patients used
azathioprine, and 42.3% used hydroxychloroquine. In
contrast, the treatment used by those with inactive
disease included hydroxychloroquine (61.5%), methotrex-
ate (7.7%) and low-dose prednisone (65.4%). More
detailed information about the clinical characteristics and
clinical medications is provided in the Supplementary
Table S1. Informed consent was obtained from all
participants, and the study was approved by the
UNIFESP Ethics Committee (CEP #0037/06).
Phenotypic evaluation of peripheral T lymphocytes
Peripheral blood mononuclear cells (PBMC) were
isolated by density gradient centrifugation in Ficoll
PaqueTM Plus (GE Healthcare Life Science, USA).
PBMCs were washed in phosphate-buffered saline and
0.56106 cells were incubated with fluorescein isothio-
cyanate (FITC) or allophycocyanin (APC)-labeled anti-
CD127, APC-Cy3-labeled anti-CD3, peridinin chlorophyll
(PerCP)-labeled anti-CD4, and phycoerythrin (PE)-Cy7-
labeled anti-CD25 antibodies (Becton Dickinson, USA),
according to the manufacturer’s instructions. After 30 min
of incubation at 46C, cells were washed with magnetic cell
sorting (MACS) buffer, fixed and permeabilized with
FoxP3 fixation/permeabilization buffer (eBioscience,
USA), and then processed for FoxP3 staining using a
kit containing APC-labeled anti-FoxP3 antibodies
(eBioscience) according to the manufacturer’s instruc-
tions. PE-labeled anti-CTLA-4, anti-PD1, anti-CD45RO,
and anti-HLA-DR monoclonal antibodies and FITC-
labeled monoclonal antibodies to GITR, OX40, CD40L,
CD28, and CD95 (Becton Dickinson) were used for
phenotypic evaluation of TREG and effector T cells
following the same labeling protocol described above.
Cells were processed using a FACSCanto flow cytometer
(Becton Dickinson), and the acquired data were analyzed
using the FlowJo software (Tree Star Inc., USA).
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Statistical analysis
Data are reported as means±SD. Statistical analysis
was performed using one-way analysis of variance
(ANOVA) for parametric variables and the Kruskal-
Wallis test for non-parametric variables. Differences were
considered to be significant if P values were 0.05 or less.
Data analysis was performed using the Prism 5.0
software (GraphPad Software, USA).
Results
Frequency and phenotypic evaluation of peripheral
blood CD25+/hiCD127-/lowFoxP3+ TREG cells in
SLE
The gate strategy for TREG cell quantification was
based on CD25 and CD127 expression, as shown in
Figure 1. In the present study, we designated
CD25+CD127Ø/lowFoxP3+ cells as TREG-I cells and
CD25highCD127Ø/lowFoxP3+ cells as TREG-II cells. The
frequencies of these two TREG subsets were similar
in A-SLE, I-SLE, and healthy controls (Figure 2).
In order to further characterize TREG cells based on
the expression of regulatory, effector, and activation
molecules, we determined the frequencies of TREG cells
bearing CTLA-4, PD1, GITR, OX40, CD40L, CD28,
CD95, CD45RO, and HLA-DR in both SLE patients and
healthy controls. We observed that most TREG-I and
TREG-II cells consistently expressed CD95, approxi-
mately half expressed CD45RO, and about one-third
expressed HLA-DR, with no significant differences
between SLE patients and healthy controls (Table 1).
Almost all TREG cells were CD28+, and there was a
decreased frequency of CD28+ TREG cells in the A-SLE
group compared with healthy controls (Figure 3A). In
addition there was an increased relative frequency of
CD40L+ TREG-I and TREG-II cells in A-SLE patients
compared with I-SLE and healthy controls (Figure 3B).
The frequency of CTLA-4+ TREG-I cells was lower in A-
SLE patients than in healthy controls (Figure 3C). Disease
activity, as assessed by SLEDAI, was weakly correlated
with the frequency of CD40L+ TREG-I cells (Figure 4) but
not with the frequency of other TREG cell subsets (data
not shown). There was an increased relative frequency of
OX40+ TREG-I in I-SLE patients compared to A-SLE and
healthy controls (Figure 5), but no differences were
observed in the frequencies of GITR+ TREG cells,
OX40+ TREG cells, and PD1+ TREG cells between
SLE patients and healthy controls (Figure 5). The
representative flow cytometry dot plots of the evaluated
molecules can be seen in Supplementary Figure S1.
Altered ratio of TREG cells to effector T cells in SLE
patients and healthy controls according to surface
phenotype
We determined the ratios of TREG to effector T cells
bearing CD40L, CD28, GITR, OX40, PD1, CD45RO,
HLA-DR, and CD95 surface molecules in both SLE
patients and healthy controls. There were significantly
lower TREG-I/effector T and TREG-II/effector T ratios for
CD45RO+ cells in patients with A-SLE and I-SLE
compared with healthy controls (Figure 6A). There was
also a lower TREG-I/effector T ratio for HLA-DR+ cells in
A-SLE compared with I-SLE and healthy controls (Figure
6B). With respect to the effector molecules GITR and
OX40, there were significantly lower TREG-I/effector T
ratios for GITR+ cells and for OX40+ cells in A-SLE
patients compared with healthy controls (Figure 6C and D,
respectively). Finally, there was a higher TREG-I and
TREG-II/effector T ratio for CD40L+ cells in A-SLE
compared to I-SLE and healthy controls (Figure 6E).
The TREG/effector T ratio for PD1+ cells did not differ
between the groups (Figure 6F).
Discussion
Modulation of the functional properties of TREG and
effector T cells is associated with variation in the
expression of several membrane molecules (19-22). In
the present study, we investigated the phenotypic profile
of membrane molecules associated with functional
activation and inhibition of TREG and effector T cells.
Using a highly specific strategy for TREG cell identifica-
tion based on the surface markers CD25+CD127Ø/low
Figure 1. Multi-parameter strategy of analysis to identify TREG
cells. A representative healthy control sample was analyzed by
flow cytometry according to the expression of CD4, CD25, CD127,
and FoxP3. CD25+ and CD25high cell subsets presented distinct
frequency of CD127Ø/low cells and in both subsets the CD127Ø/low
phenotype was associated with high FoxP3 expression.
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(5-7,25), we could not find any abnormality in TREG cell
frequency, but we originally identified a series of peculiar
qualitative differences in the composition of surface
molecules of TREG cells in SLE patients. Most TREG
cells consistently expressed CD95, approximately half
were CD45RO+, and one-third were HLA-DR+ in SLE
patients and healthy controls. There was no difference
between SLE and healthy controls regarding the frequen-
cies of GITR+ TREG cells, OX40+ TREG cells, and
PD1+ TREG cells. In contrast, samples from SLE
patients exhibited lower frequencies of CD28+ TREG
and CTLA-4+ TREG cells compared with those from
healthy controls. In addition there was an increased
frequency of CD40L+ TREG cells in samples from SLE
patients, and the frequency of CD40L+ TREG cells was
correlated with disease activity.
The reduced frequency of CTLA-4+ TREG cells in A-
SLE is consistent with the previous demonstration of
reduced CTLA-4 mRNA in CD4+CD25+ cells from SLE
patients with active disease (12). The importance of
CTLA-4 for TREG cell function was emphasized by Wing
et al. (19), who showed that natural TREG cells may
require CTLA-4 to suppress immune responses by
affecting the ability of antigen-presenting cells to activate
other T cells. CTLA-4 deficiency in TREG cells alone is
sufficient to cause fatal autoimmune disease, whereas
additional CTLA-4 deficiency in nonTREG cells improves
the disease but was not sufficient to prevent autoimmunity
in mice.
An accurate strategy for TREG cell identification by
flow cytometry is critical to obtain meaningful results.
CD127 expression has been shown to contribute to the
distinction between effector T cells (CD127+) and TREG
cells (CD127Ø/low) (5,6,25). Recently, we were able to
show that this strategy is critical for appropriate TREG cell
identification in patients with active SLE (7). We have
shown that CD25 expression is a weak criterion for TREG
cell identification in patients with active SLE in whom even
the T cell subset with highest CD25 expression contained
a large proportion of FoxP3Ø cells (7).
Recent studies using well-defined TREG cell markers
have not identified any major functional defect of TREG
cells in human SLE; rather, they demonstrated abnormal
resistance of effector T cells to immune suppression by
TREG cells (13,17,18) and altered relative ratios of TREG
versus effector T cells in these patients (26). The present
study contributes to this scenario by showing an
increased frequency of TREG cells expressing CD40L in
A-SLE patients compared with healthy controls and I-SLE
patients, and a positive but weak correlation between the
frequency of CD40L+ CD25+CD127Ø/lowFoxP3+ and
disease activity. The CD25+CD127Ø/lowFoxP3+ pheno-
type is exhibited not only by TREG cells but also by a
significant fraction of activated effector T cells, especially
in SLE (7). In fact, increased CD40L expression and
increased frequency of CD40L+ effector T cells have
been investigated in association with SLE pathophysiol-
ogy (27,28). Blockade of the CD154/CD40 pathway was
recently shown to reduce autoantibody production and to
contribute to decreased disease activity (29,30). These
observations suggest that the increased frequency of
CD40L+ TREG cells reported here may be related to SLE
disease activity.
Figure 2. Patients with active SLE (A-SLE), inactive SLE (I-SLE),
and healthy controls (HC) display equivalent frequency of TREG
cells. The relative frequency of TREG-I (CD25+CD127Ø/lowFoxP3+)
and TREG-II (CD25highCD127Ø/lowFoxP3+) cells was calculated over
total CD4+ cells. Horizontal lines indicate means and standard
deviation, respectively.
Table 1. Relative frequency of TREG cells expressing HLA-DR, CD45RO, and CD95 in patients with SLE and HC.
Surface molecules TREG cell subset Group of individuals
HC I-SLE A-SLE
HLA-DR TREG I 22.60 (12.25) 26.33 (13.84) 25.59 (12.22)
TREG II 35.55 (14.31) 33.06 (19.43) 29.15 (17.51)
CD45RO TREG I 53.79 (14.43) 54.44 (16.5) 52.05 (20.79)
TREG II 59.59 (17.80) 60.39 (12.46) 52.05 (20.79)
CD95 TREG I 68.95 (10.04) 72.63 (16.15) 74.01 (12.63)
TREG II 73.64 (11.35) 66.46 (24.99) 71.04 (24.99)
HC: healthy control; I-SLE: inactive systemic lupus erythematosus (SLEDAI=0); A-SLE: active systemic lupus erythematosus
(SLEDAI.6); TREG-I: (CD25+CD127Ø/lowFoxP3+); TREG-II (CD25highCD127Ø/lowFoxP3+). Data are reported as means and
standard deviation of relative frequency of TREG I and TREG II positive for each molecule. There were no significant differences
among groups (Kruskall-Wallis test).
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Patients with quiescent SLE displayed a higher
frequency of OX40+ TREG cells compared with healthy
controls. A recent study showed that OX40 costimulation
did not significantly affect the proliferation or survival of
naturally arising FoxP3+ TREG cells, but it profoundly
inhibited FoxP3 gene expression (31), which can affect the
transcriptional stability and functional behavior of TREG
cells during the course of the disease. OX40, GITR, and
CD40L are members of the TNF receptor super-family and
play an important role in the immune response of effector
and TREG cells. The expression of these molecules could
make effector T cells more pro-inflammatory and resistant
to immune-regulation by TREG cells, whereas these
molecules seem to be important for TREG cell proliferation
and survival. Manipulation of these molecules in normal
mice can lead to tolerance breakdown and induction of
autoimmune disease similar to that produced by TREG cell
depletion (32,33).
Figure 3. Analysis of the frequency of TREG-I (CD25+
CD127Ø/lowFoxP3+) and TREG-II (CD25highCD127Ø/lowFoxP3+)
cells expressing CD28 (A), CD40L (B), and CTLA-4 (C) in
patients with active SLE (A-SLE), inactive SLE (I-SLE), and
healthy controls (HC). The relative frequency of CD28+,
CD40L+, and CTLA-4+ cells was calculated over total TREG-I
and TREG-II, respectively. Horizontal bars indicate means and
standard deviation, respectively. *P,0.05; **P,0.01; ***P,0.001
(Kruskal-Wallis test).
Figure 4. Correlation between the relative frequency of CD40L+
TREG-I cells and disease activity (SLEDAI) in patients with SLE.
The relative frequency of CD40L+ TREG-I cells was calculated
over total TREG-I (CD25+CD127Ø/lowFoxP3+). The Spearman
correlation test was used for analysis.
Figure 5. Analysis of the frequency of TREG-I (CD25+
CD127low/ØFoxP3+) and TREG-II (CD25highCD127low/ØFoxP3+)
cells expressing OX40 (A), PD1 (B), and GITR (C) in patients with
active SLE (A-SLE), inactive SLE (I-SLE), and healthy controls
(HC). The relative frequency of OX40+, PD1+, and GITR+ cells
was calculated over total TREG-I and TREG-II, respectively.
Horizontal bars indicate means and standard deviation, respec-
tively. *P,0.05 (Kruskal-Wallis test).
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There was a lower frequency of CD28+ TREG cells in
A-SLE compared to healthy controls, which indirectly
points to higher levels of CD28null TREG cells in A-SLE.
Loss of the CD28 molecule by CD4 cells is a hallmark of
SLE. In fact, several studies have shown that the
sustained stimulation of lymphocytes in chronic inflam-
matory processes may lead to loss of CD28 expression by
CD4+ cells, which acquire alternate functions with
pathogenic features and decreased susceptibility to
immune regulation (34). Such CD4+CD28null cells could
be considered immune-senescent populations that may
contribute to the development and exacerbation of
autoimmunity. The CD28 molecule is also important in
the generation of natural TREG cells, since naive CD28-
deficient CD4 T cells are deficient in upregulating FoxP3
in response to antigen and transforming growth factor
beta (35). Therefore, the low frequency of CD28+ TREG
cells may implicate decreased immune regulatory function
in SLE patients with active disease.
In theory, immune responses are largely influenced by
the final balance between TREG and effector T cell
function. Taking this point into consideration, we aimed to
evaluate the ratio of TREG to effector T cells according to
the expression of a collection of molecules that is
biologically important for these cell subsets. We observed
a gain in the memory subset CD45RO+ favoring effector
T cells over TREG cells in SLE patients. This finding is
compatible with the high turnover of newly produced
TREG cells (CD45ROØ TREG cells) and a relative
decrease in the replacement of new naive effector T
cells, which was probably a consequence of limited
immune space for newly generated cells, maintenance
of activated effector cells, or decreased thymic output of
novel T cells in SLE (36). Accordingly, we also showed a
decreased ratio of TREG to effector T cells expressing the
late activation marker HLA-DR and the effector molecules
OX40 and GITR in A-SLE patients. This is the first
demonstration of an imbalance favoring memory and
activated TREG cells over effector T cells in SLE. A gain
in memory and activated phenotypes for effector T cells
over TREG cells may be an important indicator of an
unbalanced immune system in SLE that favors the
effector proinflammatory pathway.
Several pieces of evidence indicate that deficiency or
dysfunction of TREG cells produced by genetic abnormal-
ities or environmental insults, even for a short period of
time, could be sufficient to trigger autoimmunity in animal
models (35,37). The present demonstration of several
qualitative alterations in TREG cell surface molecules in
SLE patients might indicate functional impairment that
could contribute to disease pathophysiology. The cross-
sectional nature of this study precludes any conclusion
regarding a possible causal role for these abnormalities.
Further studies are necessary to exclude the possibility that
these abnormalities could be secondary to the immune
disturbance specific to SLE or even to immunosuppressant
therapy. This preliminary study did not include SLE patients
with active disease and under no treatment due to the
difficulty in finding those patients. Further studies are
planned to extend this study to those rare patients.
In summary, the present study demonstrated that SLE
patients with active disease exhibit an imbalance between
TREG and effector T cells in the expression of several
phenotypic markers, including CTLA-4, CD40L, GITR,
and OX40. These abnormalities may be relevant to the
pathogenesis of SLE. In particular, the increased ratio of
CD40L+ TREG to CD40L+ effector T cells in patients
with active SLE is compatible with a scenario in which
effector T cells would become more proinflammatory and
resistant to immune regulation by TREG cells. Recently,
major progress has been made in understanding the
crucial role of TREG cells in the development of
autoimmunity. The abnormalities reported here in the
expression of functionally critical molecules by TREG and
Figure 6. Ratio of TREG-I (CD25+CD127Ø/low
FoxP3+) or TREG-II (CD25highCD127Ø/low
FoxP3+) cells to effector T cells expressing
CD45RO (A), HLA-DR (B), GITR (C), OX40
(D), CD40L (E), and PD1 (F) in patients with
active SLE (A-SLE), inactive SLE (I-SLE), and
healthy controls (HC). Horizontal bars indicate
means and standard deviation, respectively. Teff:
effector T cells. *P,0.05 (Kruskall-Wallis test).
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effector T cells may represent an additional piece to help
solving the puzzle of SLE pathophysiology.
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Click here to view [pdf].
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